Observational Study to Evaluate Long-term Follow-up of Subjects Implanted With Sustained-release Bimatoprost With the SpyGlass IOL in Subjects With Ocular Hypertension or Mild-to-moderate Open-angle Glaucoma
Latest Information Update: 15 Sep 2025
At a glance
- Drugs Bimatoprost (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Therapeutic Use
- Sponsors SpyGlass Pharma
Most Recent Events
- 15 Sep 2025 New trial record